论文部分内容阅读
目的:分析不同糖耐量水平者血清C反应蛋白水平及阿卡波糖干预的影响。方法:选取从2012年6月-2015年6月151例受试者,采取OGTT(口服75g葡萄糖耐量试验)确诊88例IGT(糖耐量低减)、43例NGT(糖耐量正常),20例2型DM(2型糖尿病),其中IGT58例行16周双盲、安慰剂对照、随机、阿卡波糖干预治疗,使用免疫散射比浊法对血清CRP(C反应蛋白)进行测定。结果:血清C反应蛋白同TG、TC、2h PBG呈正相关(r=0.273、0.176、0.345,P<0.05),与HDL-C、FBG、BMI无明显相关性。干预组FBG、P2h BG、Hb A1C、CRP明显低于对照组(P<0.05)。结论:对IGT患者给予阿卡波糖干预治疗,能明显改善糖代谢,降低血清C反应蛋白水平;血清C反应蛋白同TG、TC、Hb A1C以及2h FBG呈正相关;血清C反应蛋白水平随糖耐量损伤加重而升高。
Objective: To analyze the effects of acarbose on the levels of serum C-reactive protein in patients with different glucose tolerance levels. Methods: Fifty-one subjects from June 2012 to June 2015 were enrolled in this study. Eighty-one patients with IGT (impaired glucose tolerance), 43 patients with NGT (normal glucose tolerance) and 20 patients with normal glucose tolerance (OGTT) Type 2 DM (type 2 diabetes). IGT58 was given a 16-week double-blind, placebo-controlled, placebo-controlled, randomized, acarbose-based intervention. Serum CRP (C-reactive protein) was determined by immunomagnetic nephelometry. Results: Serum C-reactive protein was positively correlated with TG, TC, 2h PBG (r = 0.273,0.176,0.345, P <0.05), but not with HDL-C, FBG and BMI. The levels of FBG, P2h BG, Hb A1C and CRP in the intervention group were significantly lower than those in the control group (P <0.05). Conclusion: Acarbose intervention in IGT patients can significantly improve glucose metabolism and reduce serum C-reactive protein levels; serum C-reactive protein is positively correlated with TG, TC, Hb A1C and 2h FBG; serum C-reactive protein level with the sugar Increased tolerance damage increased.